LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China
SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)--LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients…